Category Archives: Reviews

Food & Dining: ‘Top 100 Independent Restaurants’

2020 Rankings – October 20, 2020

RB’s Top 100 Independents ranking is a measure of the highest-grossing independent restaurants. Only restaurant concepts with no more than five locations are considered “independents” for the purpose of this list (although it’s possible a restaurant that shares a name with a chain but is owned and operated separately would qualify, such as Smith & Wollensky in New York City). Rankings are based on gross 2018 food and beverage sales. Information was gathered through surveys. When data wasn’t provided, sales were estimated based on public information, similar concepts and other factors.

Read full list

Infographic: ‘Functional Neurological Disorder’ – Signs & Symptoms (BMJ)

What you need to know

  • Functional neurological disorder (FND) is associated with considerable distress and disability. The symptoms are not faked
  • Diagnose FND positively on the basis of typical clinical features. It is not a diagnosis of exclusion
  • FND can be diagnosed and treated in presence of comorbid, pathophysiologically defined disease
  • Psychological stressors are important risk factors but are neither necessary nor sufficient for the diagnosis

Functional disorders are conditions whose origin arises primarily from a disorder of nervous system functioning rather than clearly identifiable pathophysiological disease—such as irritable bowel syndrome, fibromyalgia, and functional neurological disorder (FND)—they are the second commonest reason for new neurology consultations.1 FND is common in emergency settings,2 stroke,3 and rehabilitation services.4 It causes considerable physical disability and distress, and often places an economic burden both on patients and health services.5 Many clinicians have had little formal clinical education on the assessment and management of these disorders, and patients are often not offered potentially effective treatments.

Read more

Personal Technology: Comparing iPhone 12 Vs iPhone 12 Pro (WSJ Video)

To get those crazy-fast 5G speeds on Apple’s iPhone 12 and iPhone 12 Pro, you have to find the 5G. So WSJ’s Joanna Stern set up on the field at MetLife Stadium to put the new phones — including their cameras and improved durable body — through the paces.

Lifestyle: ‘The Monocle Book Of Gentle Living’

The Monocle Book of Gentle Living is a handbook to help you think about how to reconnect, make good things happen, to do something you care about and discover nice places and extraordinary people along the way.

Sometimes the fixes are simple and personal: to run, dive into a lake, sleep more or set aside some time with the people who make us happy. Maybe it’s about eating food from producers who are proud of its provenance or building spaces into cities that respect older residents and value younger ones. Our editors have brought all this together in one simple book – so how about taking a few moments away from the crush to flick through the pages? Gently does it, now.

Read more

Medicine: ‘The Future Of Neurosurgery’ (Video)

NYU Langone’s Kimmel Pavilion is home to the region’s newest and most technologically sophisticated neurosurgery suite. Designed to optimize patient care, our facilities are just one reason U.S. News & World Report’s “Best Hospitals” ranks NYU Langone among the top 10 hospitals in the country for neurology and neurosurgery.

Learn more about neurosurgery at NYU Langone and meet our renowned surgeons: https://nyulangone.org/locations/neur…SHOW LESS

Prescription Drugs: ‘Why They Remain High-Priced’

By Kerry Dooley Young (September 28, 2020)

There may be few issues that unite Americans ahead of the 2020 election as do their concerns about the cost of prescription drugs.

A clear majority — 75% — of respondents to a July survey said the cost of prescription medicines would be among the factors likely to influence their votes this year, according to a report from Gallup and the nonprofit West Health. Gallup reported on results from 1,007 interviews conducted with adults between July 1 and July 24.

1. What are the 2020 presidential candidates saying they will do to lower drug prices?

Both President Donald Trump, a Republican, and former Vice President Joe Biden, a Democrat, have highlighted insulin costs in their discussions of the need to lower drug prices.

In a January interview with the New York Times editorial board, Biden noted the widespread discontent among Americans about sticker shock often experienced at pharmacies. He spoke of a need for the federal government to act to make medicines more affordable.

“This is a place where I find, whether you’re Republican or Democrat, you think you’re getting screwed on drug prices. And you are, in terms of everything from insulin to inhalers and a whole range of other things,” Biden said. “So, again, can I guarantee that it gets done? No, but I can tell you what, if anybody can get it done, I can, and I think there’s a consensus for it.”

2. Why doesn’t Medicare, the biggest U.S. purchaser of drugs, directly negotiate on drug prices?

Congress has taken different approaches in designing the terms under which the two largest federal health programs, Medicaid and Medicare, buy drugs.

Medicaid is a program run by states with federal contributions and oversight. It covers people with low incomes and disabilities. Almost 67 million people were enrolled in Medicaid as of May 2020, including about 29 million children. In 1990 Congress decided that drugmakers who want to have their products covered by Medicaid must give rebates to the government. The initial rebate is equal to 23.1% of the average manufacturer price (AMP) for most drugs, or the AMP minus the best price provided to most other private-sector payers, whichever is greater. An additional rebate kicks in when prices rise faster than general inflation.

3. What’s the deal with rebates and discounts?

There’s widespread frustration among lawmakers and policy analysts about the lack of clarity about the role of middlemen in the supply chain for medicines. Known as pharmacy benefit managers (PBMs), these businesses describe the aim of their business as making drugs more affordable for consumers. Insurers like Cigna and UnitedHealth operate some of the nation’s largest PBMs, as does pharmacy giant CVS Health, which also owns insurer Aetna.

“They will tell you their mission is to lower drug costs,” said Rep. Earl L. “Buddy” Carter, a Georgia Republican, a pharmacist and a critic of PBMs, in a speech on the House floor last year. “My question to you would be: How is that working out?”

4. What is the “distinctly American” phenomenon of specialty drugs?

Kesselheim also has written on what he terms “Specialty Drugs — A Distinctly American Phenomenon.” That’s the title of a 2020 paper in the New England Journal of Medicine Kesselheim authored with Huseyin Naci, an associate professor of health policy at the London School of Economics.

In this Perspective article, Kesselheim and Naci look at how the “specialty” designation morphed from its origin in the 1970s. It then referred to a need for extra steps for preparation and delivery of new injectable and infusion products.

5. How much does it cost to bring a new drug to market anyway? 

The median cost for a medicine developed in recent years was $985 million, according to a study published in JAMA in March 2020, “Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.”

“Rising drug prices have attracted public debate in the United States and abroad on fairness of drug pricing and revenues,” write the study’s authors: Olivier J. Wouters of the London School of Economics; Martin McKee of the London School of Hygiene and Tropical Medicine; and Jeroen Luyten of Leuven Institute for Healthcare Policy, KU Leuven, Belgium. “Central to this debate is the scale of research and development investment by companies that is required to bring new medicines to market.”

Read full article